Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.91
NYSE:BAX's Cash to Debt is ranked lower than
54% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. NYSE:BAX: 0.91 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:BAX' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.31 Max: 1.13
Current: 0.91
0.09
1.13
Equity to Asset 0.55
NYSE:BAX's Equity to Asset is ranked lower than
55% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NYSE:BAX: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:BAX' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.34 Max: 0.55
Current: 0.55
0.22
0.55
Interest Coverage 5.85
NYSE:BAX's Interest Coverage is ranked lower than
81% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.77 vs. NYSE:BAX: 5.85 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BAX' s Interest Coverage Range Over the Past 10 Years
Min: 3.08  Med: 17.86 Max: 32.02
Current: 5.85
3.08
32.02
F-Score: 4
Z-Score: 5.25
M-Score: -2.36
WACC vs ROIC
6.57%
6.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 6.13
NYSE:BAX's Operating margin (%) is ranked higher than
56% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.89 vs. NYSE:BAX: 6.13 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:BAX' s Operating margin (%) Range Over the Past 10 Years
Min: 4.5  Med: 18.5 Max: 22.9
Current: 6.13
4.5
22.9
Net-margin (%) 48.68
NYSE:BAX's Net-margin (%) is ranked higher than
98% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. NYSE:BAX: 48.68 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:BAX' s Net-margin (%) Range Over the Past 10 Years
Min: 9.71  Med: 15.07 Max: 48.68
Current: 48.68
9.71
48.68
ROE (%) 57.46
NYSE:BAX's ROE (%) is ranked higher than
97% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.88 vs. NYSE:BAX: 57.46 )
Ranked among companies with meaningful ROE (%) only.
NYSE:BAX' s ROE (%) Range Over the Past 10 Years
Min: 11.41  Med: 28.27 Max: 57.46
Current: 57.46
11.41
57.46
ROA (%) 27.29
NYSE:BAX's ROA (%) is ranked higher than
98% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.61 vs. NYSE:BAX: 27.29 )
Ranked among companies with meaningful ROA (%) only.
NYSE:BAX' s ROA (%) Range Over the Past 10 Years
Min: 4.13  Med: 10.79 Max: 27.29
Current: 27.29
4.13
27.29
ROC (Joel Greenblatt) (%) 83.11
NYSE:BAX's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.16 vs. NYSE:BAX: 83.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:BAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 6.58  Med: 37.11 Max: 83.11
Current: 83.11
6.58
83.11
Revenue Growth (3Y)(%) -10.70
NYSE:BAX's Revenue Growth (3Y)(%) is ranked lower than
82% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. NYSE:BAX: -10.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:BAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.7  Med: 7.6 Max: 17.3
Current: -10.7
-10.7
17.3
EBITDA Growth (3Y)(%) -28.60
NYSE:BAX's EBITDA Growth (3Y)(%) is ranked lower than
89% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. NYSE:BAX: -28.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:BAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.6  Med: 7 Max: 33.1
Current: -28.6
-28.6
33.1
EPS Growth (3Y)(%) -44.00
NYSE:BAX's EPS Growth (3Y)(%) is ranked lower than
92% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. NYSE:BAX: -44.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:BAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44  Med: 7.1 Max: 61.5
Current: -44
-44
61.5
» NYSE:BAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

BAX Guru Trades in Q4 2015

Steven Cohen 888,700 sh (New)
Lee Ainslie 30,140 sh (New)
David Einhorn 503,500 sh (New)
Louis Moore Bacon 620,000 sh (+195.24%)
Tom Gayner 22,000 sh (+120.00%)
Vanguard Health Care Fund 9,558,280 sh (+32.84%)
Charles Brandes 315,373 sh (+1.20%)
Murray Stahl 14,022 sh (+0.36%)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Daniel Loeb 53,850,000 sh (unchged)
John Hussman Sold Out
Paul Tudor Jones 79,893 sh (-0.05%)
Tweedy Browne 2,495,682 sh (-0.10%)
Mario Gabelli 156,900 sh (-0.60%)
John Buckingham 85,849 sh (-1.76%)
Mairs and Power 2,252,752 sh (-1.98%)
Richard Pzena 4,736,982 sh (-2.60%)
George Soros 495,000 sh (-2.88%)
John Rogers 63,595 sh (-4.12%)
Jeremy Grantham 52,246 sh (-5.09%)
Jeff Auxier 20,831 sh (-15.43%)
Manning & Napier Advisors, Inc 160,214 sh (-21.19%)
First Eagle Investment 808,879 sh (-23.45%)
Jim Simons 492,132 sh (-32.42%)
Keeley Asset Management Corp 50,550 sh (-38.43%)
Jana Partners 5,709,178 sh (-54.62%)
» More
Q1 2016

BAX Guru Trades in Q1 2016

Joel Greenblatt 1,695,068 sh (New)
David Einhorn 1,198,663 sh (+138.07%)
Keeley Asset Management Corp 61,500 sh (+21.66%)
Vanguard Health Care Fund 11,176,980 sh (+16.94%)
Jim Simons 517,032 sh (+5.06%)
Murray Stahl 14,122 sh (+0.71%)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Tom Gayner 22,000 sh (unchged)
Daniel Loeb 53,850,000 sh (unchged)
John Rogers Sold Out
Jeff Auxier Sold Out
Jana Partners Sold Out
Louis Moore Bacon Sold Out
Lee Ainslie Sold Out
Tweedy Browne 2,492,683 sh (-0.12%)
Charles Brandes 310,615 sh (-1.51%)
Mario Gabelli 153,750 sh (-2.01%)
John Buckingham 81,062 sh (-5.58%)
Manning & Napier Advisors, Inc 149,096 sh (-6.94%)
George Soros 448,200 sh (-9.45%)
Mairs and Power 2,035,912 sh (-9.63%)
Richard Pzena 4,084,406 sh (-13.78%)
Paul Tudor Jones 64,681 sh (-19.04%)
Jeremy Grantham 32,592 sh (-37.62%)
Steven Cohen 51,000 sh (-94.26%)
First Eagle Investment 1,100 sh (-99.86%)
» More
Q2 2016

BAX Guru Trades in Q2 2016

John Hussman 175,000 sh (New)
Leucadia National 700,000 sh (New)
Lee Ainslie 73,700 sh (New)
First Eagle Investment 2,129,733 sh (+193512.09%)
Jim Simons 583,200 sh (+12.80%)
Jeremy Grantham 36,465 sh (+11.88%)
Tom Gayner 22,000 sh (unchged)
Murray Stahl 14,122 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
John Buckingham Sold Out
David Einhorn Sold Out
Tweedy Browne Global Value 1,055,212 sh (-3.62%)
Daniel Loeb 51,901,767 sh (-3.62%)
Tweedy Browne 2,393,665 sh (-3.97%)
Mairs and Power 1,948,504 sh (-4.29%)
Keeley Asset Management Corp 58,610 sh (-4.70%)
Mario Gabelli 125,100 sh (-18.63%)
Richard Pzena 3,115,865 sh (-23.71%)
George Soros 284,327 sh (-36.56%)
Vanguard Health Care Fund 7,053,480 sh (-36.89%)
Joel Greenblatt 849,128 sh (-49.91%)
Paul Tudor Jones 27,459 sh (-57.55%)
Charles Brandes 75,584 sh (-75.67%)
Steven Cohen 3,600 sh (-92.94%)
» More
Q3 2016

BAX Guru Trades in Q3 2016

Steven Cohen 227,300 sh (+6213.89%)
First Eagle Investment 2,635,577 sh (+23.75%)
Paul Tudor Jones 33,174 sh (+20.81%)
John Hussman 200,000 sh (+14.29%)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Tom Gayner 22,000 sh (unchged)
Daniel Loeb 51,901,767 sh (unchged)
Murray Stahl 14,122 sh (unchged)
Jeremy Grantham Sold Out
Charles Brandes Sold Out
Leucadia National Sold Out
Mario Gabelli 123,500 sh (-1.28%)
Keeley Asset Management Corp 57,410 sh (-2.05%)
Mairs and Power 1,903,688 sh (-2.30%)
Lee Ainslie 67,360 sh (-8.60%)
Tweedy Browne 2,157,391 sh (-9.87%)
George Soros 254,327 sh (-10.55%)
Joel Greenblatt 638,063 sh (-24.86%)
Vanguard Health Care Fund 4,902,940 sh (-30.49%)
Richard Pzena 1,061,577 sh (-65.93%)
Jim Simons 158,000 sh (-72.91%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:ESLOY, NAS:ILMN, NYSE:BCR, NYSE:BDX, NAS:XRAY, OTCPK:TRUMF, OTCPK:OCPNY, NYSE:WAT, NYSE:MTD, NAS:HOLX, OTCPK:RSMDF, NYSE:COO, NYSE:WST, OTCPK:SAUHY, NYSE:STE, OTCPK:GNGBY, NYSE:HRC, NYSE:CMN, OTCPK:ANSLY, NAS:ICUI » details
Traded in other countries:BTL.Germany, BAX.Mexico, BAX.Switzerland, 0QK8.UK,
Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.

Baxter International Inc was incorporated in Delaware in 1931. The Company is a healthcare company. It is engaged in the development, manufacture and sale of products that save and sustain the lives of people with immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products that advance patient care. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely, Hospital Products and Renal. The Hospital Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. The Renal business also offers a portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis (PD), in-center hemodialysis (HD), home HD (HHD), continuous renal replacement therapy (CRRT) and additional dialysis services. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.

Ratios

vs
industry
vs
history
P/E(ttm) 5.01
BAX's P/E(ttm) is ranked higher than
95% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.20 vs. BAX: 5.01 )
Ranked among companies with meaningful P/E(ttm) only.
BAX' s P/E(ttm) Range Over the Past 10 Years
Min: 4.86  Med: 9.58 Max: 22.53
Current: 5.01
4.86
22.53
Forward P/E 21.10
BAX's Forward P/E is ranked higher than
57% of the 35 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.22 vs. BAX: 21.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 5.04
BAX's PE(NRI) is ranked higher than
94% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.71 vs. BAX: 5.04 )
Ranked among companies with meaningful PE(NRI) only.
BAX' s PE(NRI) Range Over the Past 10 Years
Min: 4.89  Med: 10.6 Max: 115.67
Current: 5.04
4.89
115.67
Price/Owner Earnings (ttm) 6.13
BAX's Price/Owner Earnings (ttm) is ranked higher than
94% of the 81 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.97 vs. BAX: 6.13 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BAX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.65  Med: 11.78 Max: 69.54
Current: 6.13
5.65
69.54
P/B 2.81
BAX's P/B is ranked higher than
55% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. BAX: 2.81 )
Ranked among companies with meaningful P/B only.
BAX' s P/B Range Over the Past 10 Years
Min: 2.05  Med: 2.63 Max: 3.34
Current: 2.81
2.05
3.34
P/S 2.44
BAX's P/S is ranked higher than
53% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. BAX: 2.44 )
Ranked among companies with meaningful P/S only.
BAX' s P/S Range Over the Past 10 Years
Min: 1.06  Med: 1.42 Max: 2.66
Current: 2.44
1.06
2.66
PFCF 27.85
BAX's PFCF is ranked higher than
50% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.13 vs. BAX: 27.85 )
Ranked among companies with meaningful PFCF only.
BAX' s PFCF Range Over the Past 10 Years
Min: 7.08  Med: 12.49 Max: 266.13
Current: 27.85
7.08
266.13
POCF 14.96
BAX's POCF is ranked higher than
58% of the 99 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.52 vs. BAX: 14.96 )
Ranked among companies with meaningful POCF only.
BAX' s POCF Range Over the Past 10 Years
Min: 4.58  Med: 7.24 Max: 20.62
Current: 14.96
4.58
20.62
EV-to-EBIT 4.91
BAX's EV-to-EBIT is ranked higher than
96% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.32 vs. BAX: 4.91 )
Ranked among companies with meaningful EV-to-EBIT only.
BAX' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.77  Med: 8.9 Max: 15.8
Current: 4.91
4.77
15.8
EV-to-EBITDA 4.27
BAX's EV-to-EBITDA is ranked higher than
95% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.51 vs. BAX: 4.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.11  Med: 6.8 Max: 10
Current: 4.27
4.11
10
Shiller P/E 10.61
BAX's Shiller P/E is ranked higher than
93% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.02 vs. BAX: 10.61 )
Ranked among companies with meaningful Shiller P/E only.
BAX' s Shiller P/E Range Over the Past 10 Years
Min: 9.72  Med: 12.8 Max: 21.84
Current: 10.61
9.72
21.84
Current Ratio 2.53
BAX's Current Ratio is ranked higher than
53% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.44 vs. BAX: 2.53 )
Ranked among companies with meaningful Current Ratio only.
BAX' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.67 Max: 2.7
Current: 2.53
1.08
2.7
Quick Ratio 1.93
BAX's Quick Ratio is ranked higher than
59% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. BAX: 1.93 )
Ranked among companies with meaningful Quick Ratio only.
BAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.12 Max: 2.02
Current: 1.93
0.74
2.02
Days Inventory 98.38
BAX's Days Inventory is ranked higher than
65% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 122.94 vs. BAX: 98.38 )
Ranked among companies with meaningful Days Inventory only.
BAX' s Days Inventory Range Over the Past 10 Years
Min: 98.38  Med: 141.84 Max: 161.84
Current: 98.38
98.38
161.84
Days Sales Outstanding 62.71
BAX's Days Sales Outstanding is ranked higher than
50% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.71 vs. BAX: 62.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.53  Med: 64.51 Max: 78.76
Current: 62.71
58.53
78.76

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.13
BAX's Dividend Yield is ranked lower than
59% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. BAX: 1.13 )
Ranked among companies with meaningful Dividend Yield only.
BAX' s Dividend Yield Range Over the Past 10 Years
Min: 0.98  Med: 3.81 Max: 5.89
Current: 1.13
0.98
5.89
Dividend Payout 0.06
BAX's Dividend Payout is ranked higher than
98% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. BAX: 0.06 )
Ranked among companies with meaningful Dividend Payout only.
BAX' s Dividend Payout Range Over the Past 10 Years
Min: 0.02  Med: 0.43 Max: 4
Current: 0.06
0.02
4
Dividend Growth (3y) -6.80
BAX's Dividend Growth (3y) is ranked lower than
76% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. BAX: -6.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BAX' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -6.8  Med: 1.7 Max: 22.5
Current: -6.8
-6.8
22.5
Forward Dividend Yield 1.16
BAX's Forward Dividend Yield is ranked lower than
60% of the 141 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. BAX: 1.16 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.52
BAX's Yield on cost (5-Year) is ranked lower than
58% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.75 vs. BAX: 1.52 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.31  Med: 5.07 Max: 7.85
Current: 1.52
1.31
7.85
3-Year Average Share Buyback Ratio -0.10
BAX's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. BAX: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: -0.9 Max: 3.3
Current: -0.1
-2.1
3.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.06
BAX's Price/Tangible Book is ranked lower than
54% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.34 vs. BAX: 5.06 )
Ranked among companies with meaningful Price/Tangible Book only.
BAX' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.43  Med: 5.62 Max: 15.06
Current: 5.06
3.43
15.06
Price/Projected FCF 1.20
BAX's Price/Projected FCF is ranked higher than
81% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. BAX: 1.20 )
Ranked among companies with meaningful Price/Projected FCF only.
BAX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.14 Max: 2.82
Current: 1.2
0.53
2.82
Price/Median PS Value 1.72
BAX's Price/Median PS Value is ranked lower than
79% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. BAX: 1.72 )
Ranked among companies with meaningful Price/Median PS Value only.
BAX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 1 Max: 1.83
Current: 1.72
0.5
1.83
Price/Graham Number 1.07
BAX's Price/Graham Number is ranked higher than
79% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.45 vs. BAX: 1.07 )
Ranked among companies with meaningful Price/Graham Number only.
BAX' s Price/Graham Number Range Over the Past 10 Years
Min: 1.03  Med: 1.85 Max: 7
Current: 1.07
1.03
7
Earnings Yield (Greenblatt) (%) 20.01
BAX's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. BAX: 20.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 6.3  Med: 11.2 Max: 20.76
Current: 20.01
6.3
20.76
Forward Rate of Return (Yacktman) (%) 8.99
BAX's Forward Rate of Return (Yacktman) (%) is ranked lower than
51% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.00 vs. BAX: 8.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.6  Med: 14.85 Max: 28
Current: 8.99
4.6
28

More Statistics

Revenue (TTM) (Mil) $10,121
EPS (TTM) $ 8.92
Beta0.78
Short Percentage of Float1.88%
52-Week Range $34.06 - 50.16
Shares Outstanding (Mil)543.92

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 10,171 10,536 10,958
EPS ($) 1.82 2.12 2.48
EPS w/o NRI ($) 1.82 2.12 2.48
EPS Growth Rate
(3Y to 5Y Estimate)
18.51%
Dividends Per Share ($) 0.55 0.61 0.61
» More Articles for NYSE:BAX

Headlines

Articles On GuruFocus.com
10 Stocks for Using a Benjamin Graham Value Investing Strategy Dec 09 2016 
10 Low PE Stocks for the Defensive Investor Dec 08 2016 
9 Stocks First Eagle Keeps Buying Nov 10 2016 
Vanguard Health Care Fund Sells Amgen, Baxter Nov 02 2016 
Medical Companies Offer Good Value Opportunities Sep 16 2016 
10 Undervalued Stocks for the Defensive Investor Sep 13 2016 
Baxter Going Strong Aug 30 2016 
10 Stocks for Using a Benjamin Graham Value Investing Strategy Aug 24 2016 
15 Best Undervalued Stocks of the Week Aug 23 2016 
10 Undervalued Stocks for the Defensive Investor Aug 22 2016 

More From Other Websites
5 Efficient Stocks to Buy for Superlative Returns Dec 09 2016
Baxter Announces Winners of Seventh Annual LEAP Award Recognizing Hospital Pharmacies for Excellence... Dec 08 2016
Baxter to Present at the 35th Annual J.P. Morgan Healthcare Conference Dec 07 2016
Genomic Health: Cancer Test Business Strong, Q3 Dismal Dec 07 2016
5 Healthcare Stocks Billionaires Are Buying Dec 05 2016
Baxter Receives Perfect Score from Human Rights Campaign Foundation Dec 05 2016
Baxter Introduces New Safety Management System and Software Updates for Sigma Spectrum Infusion... Dec 05 2016
Boston Scientific (BSX) Inks $75 Million Deal with Neovasc Dec 05 2016
Medtronic Stock Falls on Mixed 2Q; Positive on HeartWare Buy Dec 02 2016
Is Baxter International Inc. (BAX) A Good Stock To Buy? Dec 01 2016
Baxter’s Latest Dividend and Share Repurchase Authorization Dec 01 2016
Baxter Makes Significant Advancements in Hemodialysis Treatments Dec 01 2016
Medtronic Partners UH to Launch Integrated Health Solutions Dec 01 2016
How Baxter Continues to Contribute to Patient Care Dec 01 2016
Discussing Baxter International’s Recent Stock Performance Nov 30 2016
Analysts’ Latest Recommendations for Baxter: Mostly ‘Holds’ Nov 30 2016
Baxter (BAX) Inks Partnership with Americares, Stock Down Nov 30 2016
Americares and Baxter International Foundation Announce Oral Health Project to Prevent Systemic... Nov 29 2016
NuVasive: Q3 Results Lack Shine, Spine Market Holds Promise Nov 29 2016
Edward Lifesciences (EW) to Buy Israel's Valtech Cardio Nov 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)